A detailed history of Griffin Asset Management, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Griffin Asset Management, Inc. holds 79,051 shares of BMY stock, worth $4.49 Million. This represents 0.47% of its overall portfolio holdings.

Number of Shares
79,051
Previous 82,153 3.78%
Holding current value
$4.49 Million
Previous $3.41 Million 19.91%
% of portfolio
0.47%
Previous 0.4%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

SELL
$39.66 - $51.75 $123,025 - $160,528
-3,102 Reduced 3.78%
79,051 $4.09 Million
Q2 2024

Jul 23, 2024

SELL
$40.25 - $52.99 $221,254 - $291,286
-5,497 Reduced 6.27%
82,153 $3.41 Million
Q1 2024

Apr 17, 2024

SELL
$47.98 - $54.4 $2,063 - $2,339
-43 Reduced 0.05%
87,650 $4.75 Million
Q4 2023

Jan 19, 2024

SELL
$48.48 - $57.85 $977,841 - $1.17 Million
-20,170 Reduced 18.7%
87,693 $4.5 Million
Q3 2023

Oct 19, 2023

SELL
$57.89 - $64.73 $390,468 - $436,603
-6,745 Reduced 5.89%
107,863 $6.26 Million
Q2 2023

Aug 01, 2023

BUY
$63.71 - $70.74 $864,289 - $959,658
13,566 Added 13.43%
114,608 $7.33 Million
Q1 2023

May 09, 2023

SELL
$65.71 - $74.53 $7,096 - $8,049
-108 Reduced 0.11%
101,042 $7 Million
Q4 2022

Jan 20, 2023

BUY
$68.48 - $81.09 $46,840 - $55,465
684 Added 0.68%
101,150 $0
Q3 2022

Oct 19, 2022

SELL
$0.13 - $76.84 $30 - $17,903
-233 Reduced 0.23%
100,466 $7.14 Million
Q2 2022

Jul 19, 2022

SELL
$72.62 - $79.98 $433,105 - $477,000
-5,964 Reduced 5.59%
100,699 $7.75 Million
Q1 2022

Apr 12, 2022

SELL
$61.48 - $73.72 $224,770 - $269,520
-3,656 Reduced 3.31%
106,663 $7.79 Million
Q4 2021

Jan 28, 2022

SELL
$53.63 - $62.52 $936,969 - $1.09 Million
-17,471 Reduced 13.67%
110,319 $6.88 Million
Q3 2021

Nov 05, 2021

BUY
$59.17 - $69.31 $389,752 - $456,544
6,587 Added 5.43%
127,790 $7.56 Million
Q2 2021

Jul 28, 2021

BUY
$61.91 - $67.42 $26,435 - $28,788
427 Added 0.35%
121,203 $8.1 Million
Q1 2021

May 04, 2021

SELL
$59.34 - $66.74 $406,419 - $457,102
-6,849 Reduced 5.37%
120,776 $7.63 Million
Q4 2020

Jan 27, 2021

BUY
$57.74 - $65.43 $393,902 - $446,363
6,822 Added 5.65%
127,625 $7.92 Million
Q3 2020

Nov 12, 2020

SELL
$57.43 - $63.64 $143,517 - $159,036
-2,499 Reduced 2.03%
120,803 $7.28 Million
Q2 2020

Aug 18, 2020

SELL
$54.82 - $64.09 $83,545 - $97,673
-1,524 Reduced 1.22%
123,302 $7.25 Million
Q1 2020

May 18, 2020

SELL
$46.4 - $67.43 $9,187 - $13,351
-198 Reduced 0.16%
124,826 $6.96 Million
Q4 2019

Feb 11, 2020

BUY
$49.21 - $64.19 $206,780 - $269,726
4,202 Added 3.48%
125,024 $8.03 Million
Q3 2019

Nov 05, 2019

SELL
$42.77 - $50.71 $4 Million - $4.74 Million
-93,500 Reduced 43.63%
120,822 $6.13 Million
Q2 2019

Aug 19, 2019

BUY
$44.62 - $49.34 $126,943 - $140,372
2,845 Added 1.35%
214,322 $9.72 Million
Q1 2019

May 08, 2019

BUY
$45.12 - $53.8 $483,821 - $576,897
10,723 Added 5.34%
211,477 $10.1 Million
Q4 2018

Mar 01, 2019

BUY
$48.76 - $63.23 $162,712 - $210,998
3,337 Added 1.69%
200,754 $10.4 Million
Q3 2018

Nov 19, 2018

BUY
$55.19 - $62.25 $160,934 - $181,521
2,916 Added 1.5%
197,417 $12.3 Million
Q2 2018

Aug 15, 2018

BUY
$50.53 - $62.98 $378,671 - $471,972
7,494 Added 4.01%
194,501 $10.8 Million
Q1 2018

May 16, 2018

BUY
$59.92 - $68.98 $111,091 - $127,888
1,854 Added 1.0%
187,007 $11.8 Million
Q4 2017

Feb 20, 2018

BUY
$59.94 - $65.35 $493,306 - $537,830
8,230 Added 4.65%
185,153 $11.3 Million
Q3 2017

Nov 15, 2017

BUY
$55.23 - $63.74 $350,931 - $405,003
6,354 Added 3.73%
176,923 $11.3 Million
Q2 2017

Aug 29, 2017

BUY
N/A
170,569
170,569 $9.5 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $121B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Griffin Asset Management, Inc. Portfolio

Follow Griffin Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Griffin Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Griffin Asset Management, Inc. with notifications on news.